Cambridge, United Kingdom
Ignota Labs, headquartered in the United Kingdom and founded in 2021, is pioneering advancements in the pharmaceutical and health care industries using AI technology. Their mission, succinctly captured by their slogan, "Ignota Labs rescues promising but failing drugs," underscores their commitment to reviving abandoned drugs with untapped therapeutic potential.
Their core innovation, SAFEPATH©, is a proprietary AI model that leverages bioinformatics and cheminformatics data through deep learning. This approach addresses critical safety issues in drug trials, identifying toxicity mechanisms and optimizing therapeutic balance.
Recently, Ignota Labs secured a substantial $6.90M grant investment from notable investors such as Gaingels, Montage Ventures, AIX Ventures, Blue Wire Capital, and Modi Venture Partners. This funding bolsters their strategy to expedite treatment availability by converting failed trials into successful therapeutic solutions.
